Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Schiffman

Showing results (41-50 of 498) with videos related to

Pageof 50
Sort By:
Infectious Agents and Cancer|June 3, 2009
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderlineMark Schiffman, Gary Clifford, Franco M Buonaguro
International Journal of Cancer|February 11, 2005
Re: Munoz et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective." Int J Cancer 2004;111:278-85Michelle J Khan, Rolando Herrero, Mark Schiffman
International Journal of Cancer|April 26, 2005
Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in IndiaMichelle J Khan, Mark Schiffman, Jose Jeronimo
Obstetrics and Gynecology|June 3, 2008
Interobserver agreement in the assessment of components of colposcopic gradingL Stewart Massad, Jose Jeronimo, Mark Schiffman, et al.
American Journal of Obstetrics and Gynecology|June 26, 2003
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsyJ Thomas Cox, Mark Schiffman, Diane Solomon, et al.
American Journal of Obstetrics and Gynecology|July 10, 2007
Visual appearance of the uterine cervix: correlation with human papillomavirus detection and typeJose Jeronimo, L Stewart Massad, Mark Schiffman, et al.
Preventive Medicine|July 9, 2018
How confident can we be in the current guidelines for exiting cervical screening?Patti E Gravitt, Rebecca Landy, Mark Schiffman
American Journal of Obstetrics and Gynecology|June 26, 2003
Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective studyRichard Guido, Mark Schiffman, Diane Solomon, et al.
Sexually Transmitted Diseases|September 22, 2011
Accepting the universal truths of cervical human papillomavirus epidemiology in pursuit of the remaining mysteriesMark Schiffman, Julia C Gage, Megan A Clarke
Current Problems in Cancer|August 28, 2018
The next generation of cervical cancer screening programs: Making the case for risk-based guidelinesRebecca B Perkins, Mark Schiffman, Richard S Guido
Pageof 50

Showing results (41-50 of 498) with videos related to

Sort By:
Pageof 50
Infectious Agents and Cancer|June 3, 2009
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderlineMark Schiffman, Gary Clifford, Franco M Buonaguro
International Journal of Cancer|February 11, 2005
Re: Munoz et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective." Int J Cancer 2004;111:278-85Michelle J Khan, Rolando Herrero, Mark Schiffman
International Journal of Cancer|April 26, 2005
Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in IndiaMichelle J Khan, Mark Schiffman, Jose Jeronimo
Obstetrics and Gynecology|June 3, 2008
Interobserver agreement in the assessment of components of colposcopic gradingL Stewart Massad, Jose Jeronimo, Mark Schiffman, et al.
American Journal of Obstetrics and Gynecology|June 26, 2003
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsyJ Thomas Cox, Mark Schiffman, Diane Solomon, et al.
American Journal of Obstetrics and Gynecology|July 10, 2007
Visual appearance of the uterine cervix: correlation with human papillomavirus detection and typeJose Jeronimo, L Stewart Massad, Mark Schiffman, et al.
Preventive Medicine|July 9, 2018
How confident can we be in the current guidelines for exiting cervical screening?Patti E Gravitt, Rebecca Landy, Mark Schiffman
American Journal of Obstetrics and Gynecology|June 26, 2003
Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective studyRichard Guido, Mark Schiffman, Diane Solomon, et al.
Sexually Transmitted Diseases|September 22, 2011
Accepting the universal truths of cervical human papillomavirus epidemiology in pursuit of the remaining mysteriesMark Schiffman, Julia C Gage, Megan A Clarke
Current Problems in Cancer|August 28, 2018
The next generation of cervical cancer screening programs: Making the case for risk-based guidelinesRebecca B Perkins, Mark Schiffman, Richard S Guido
Pageof 50